retatrutide peptide clinical trial results 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

doi: 10.1016/S0140-6736(21)02188-7 263 GersteinHCBoschJDagenaisGRDazRJungHMaggioniAPet al

You should be shooting for between 150 to 300 minutes of moderate activities like fast walking or riding a bike on a flat surface at a modest pace

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity

Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction 1-6

These symptoms are often more noticeable when starting the medication or increasing the dose (Reference)